Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus

被引:0
作者
Paolo Bonanni [1 ]
Jung Yeon Heo [2 ]
Hitoshi Honda [3 ]
Ping-Ing Lee [4 ]
Aminatou Mouliom [5 ]
Hoe Nam Leong [6 ]
Maria del Pilar Martin Matos [5 ]
Rachel Dawson [5 ]
机构
[1] Department of Health Sciences, University of Florence, Florence
[2] Ajou University School of Medicine, Suwon
[3] Fujita Health University School of Medicine, Toyoake
[4] Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei
[5] Moderna, Inc., 325 Binney Street, Cambridge, 02142, MA
[6] Rophi Clinic, Singapore
关键词
Co-administration; COVID-19; Influenza; Lower respiratory tract infection; Older adults; Public health; Respiratory syncytial virus; RSV; SARS-CoV-2; Vaccination;
D O I
10.1007/s40121-025-01135-0
中图分类号
学科分类号
摘要
Lower respiratory tract infections caused by SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) cause a significant disease burden globally, despite the availability of effective vaccines. Certain populations, such as older adults (≥ 60 years) and individuals of all ages with particular comorbidities, are at increased risk for severe outcomes, including hospitalization and death. National administration schedules for available vaccines against respiratory viruses are not unified, and not all current guidelines are clear and directive, concerning the optimal timing of vaccination. Herein, we formulate an evidence-based position regarding the optimal timing of COVID-19, influenza, and RSV vaccination for older adults and individuals with chronic comorbidities, based on a synthesis of the literature and current guidelines. Vaccination impact and timing were found to be influenced by vaccinee risk factors, including age and comorbidities, and waning vaccine effectiveness and seasonal pathogen burden. Because COVID-19, influenza, and RSV display unique seasonal patterns within and between regions, local epidemiological surveillance of each virus is crucial for determining optimal vaccination timing and guidelines. To maximize the benefits of these respiratory virus vaccines, the timing of peak vaccine effectiveness and period of greatest risk for severe outcomes should be aligned. Thus, COVID-19, influenza, and other recommended vaccines given ahead of the start of the respiratory virus season (or other regionally appropriate time) and co-administered at a single, routine visit represent the optimal approach to protecting at-risk populations. More data will be required to establish the clinical benefit of additional RSV vaccine doses and whether these may be integrated within a seasonal schedule. Coordinated policy decisions that align with strain selection for new and annually reformulated vaccines would enable the timely raising of public health awareness, ultimately leading to enhanced vaccine uptake. Implementation strategies will require engagement of healthcare providers and strong, evidence-based public health recommendations for integrated vaccine schedules. © The Author(s) 2025.
引用
收藏
页码:911 / 932
页数:21
相关论文
共 179 条
  • [1] Safiri S., Mahmoodpoor A., Kolahi A.A., Et al., Global burden of lower respiratory infections during the last three decades, Front Public Health, 10, (2022)
  • [2] National Health Service. Respiratory tract infections, (2024)
  • [3] The top 10 causes of death, (2024)
  • [4] CDC's updated respiratory virus guidance: what to do when you are sick, (2024)
  • [5] US Centers for Disease Control and Prevention. People at higher risk of flu complications, (2024)
  • [6] Hamilton M.A., Liu Y., Calzavara A., Et al., Predictors of all-cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2, Influenza Other Respir Viruses, 16, 6, pp. 1072-1081, (2022)
  • [7] US Centers for Disease Control and Prevention. RSV in older adults and adults with chronic medical conditions, (2024)
  • [8] European Centre for Disease Prevention and Control. Risk groups for severe influenza, (2024)
  • [9] Clinical overview of pneumococcal disease
  • [10] Ochoa-Gondar O., Torras-Vives V., de Diego-Cabanes C., Et al., Incidence and risk factors of pneumococcal pneumonia in adults: a population-based study, BMC Pulm Med, 23, 1, (2023)